Galina V. Shurin, PhD
Dr. Shurin is a member of the
Division of Clinical Immunopathology and Co-director of the departmental Flow Cytometry facility.
Research Assistant Professor of Pathology
Scaife Hall, S732
Department of Pathology
Pittsburgh, PA 15261
Office Telephone: 412-648-9841
Lab Telephone: 412-648-9831
- PhD - Immunology/Allergy, Moscow Research Institute of Epidemiology and Microbiology, Department of Molecular and Cellular Immunology, Moscow, Russia, 1991
At present time my research is focused on studies of a novel therapeutic approach on incorporation of low-dose chemotherapy into vaccine therapy, where low-dose chemotherapeutic agents modify immunogenicity of the tumor microenvironment and the immunotherapeutic component target primary and metastatic tumors and induce specific antitumor immune memory.
Our long-term goal is to develop an optimized chemoimmunotherapeutic approach for lung cancer treatment and test it in a clinical setting. In addition, we plan to understand cellular and molecular events in the lung cancer microenvironment responsible for the synergistic antitumor activity of a combination therapy in order to propose strategies for further evaluation and improvement of chemoimmunotherapy of lung cancer.
Selected PublicationsView Dr. Shurin's publications on PubMed
Song E.Y., Shurin M.R., Tourkova I.L., Chatta G.S., Gutkin D.W., Shurin G.V. Epigenetic Regulation of Dendritic Cell Chemokine CXCL14 Expression in Human Prostate Carcinoma. Cancer Research, 70(11):4394-401, 2010.
Kaneno R., Shurin GV., Kaneno FM., Naiditch H., Luo J., Shurin MR. Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell Oncol, 34(2):97-106, 2011.
Tkach AV., Shurin GV., Shurin MR., Kisin ER., Murray AR., Young SH., Star A., Fadeel B., Kagan VE., Shvedova AA. Direct effect of carbon nanotubes on dendritic cell induce immune suppression upon pulmonary exposure. ACS Nano 5(7):5755-62, 2011.
Shurin MR., Naiditch H., Zhong H., Shurin GV. Regulatory dendritic cells: new targets for cancer immunotherapy. Cancer Biol Ther. 11(11):988-92, 2011.
Naiditch H., Shurin MR., Shurin GV. Targeting myeloid regulatory cell in cancer by chemotherapeutic agents. Immunol Res. 50(2-3):276-85, 2011.
Shurin MR., Naiditch H., Gutkin DW., Umansky V., Shurin GV. ChemoImmunoModulation: immuneregulation by the antineoplastic chemotherapeutic agents. Curr Med Chem. 2012; 19(12):1792-803. Michels T., Shurin GV., Naiditch H., Sevko A., Umansky V., Shurin MR. Paclitaxel promotes differentiation of myeloid-derived suppressor cell into dendritic cells in vitro in a TLR4-independent manner. J. Immunotoxicol, 2012.
Sevko A., Kremer V., Falk C., Umansky L., Shurin MR., Shurin GV., Umansky V. Application of paclitaxel in low non-cytotoxic doses suppots vaccination with melanoma antigens in normal mice. J. Immunotoxicol, 9(3):275-281, 2012.
Tkach AV., Yanamala N., Stanley S., Shurin MR., Shurin GV., Kisisn ER., Murray AR., Pareso S., Khaliullin T., Kotchey GP., Castranova V., Mathur S., Fadeel B., Star A., Kagan VE., Shvedova AA. Graphene Oxide, but not Fullerenes, targets immunoproteasomes and suppresses antigen presentation by dendritic cells. Small, 2012
Shvedova AA., Tkach AV., Kisisn ER., Khaliullin T., Stanley S., Gutkin DW., Star A., Chen Y., Shurin GV., Kagan VE., Shurin MR. Carbon nanotubes enhance metastatic growth of lung carcinoma via up-regulation of myeloid-derived suppressor cells. Small, 2012.
Sevco A., Michels T., Vrohlings M., Umansky V., Beckhove P., Kato M., Shurin GV., Shurin MR., Umansky V. J. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. Immunol. 190(5):2464-2471, 2013.
Ustinova EE., Shurin GV., Gutkin DW., Shurin MR. The role of TLR4 in the paclitaxel effects on neuronal growth in vitro. PloS One, 8(2):e56886, 2013.
Shurin GV., Ma Y., Shurin MR. Immunosuppressive mechanisms of regulatory dendritic cells in cancer. Cancer Microenvironment, 2013 in press.